Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.

Original languageEnglish (US)
Pages (from-to)601-604
Number of pages4
JournalExpert review of vaccines
Issue number5
StatePublished - May 2011


  • West Nile virus
  • adverse events
  • elderly
  • immunogenicity
  • safety
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects'. Together they form a unique fingerprint.

Cite this